BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35622319)

  • 1. One-Step Next-Generation Sequencing of Immunoglobulin and T-Cell Receptor Gene Recombinations for MRD Marker Identification in Acute Lymphoblastic Leukemia.
    Villarese P; Abdo C; Bertrand M; Thonier F; Giraud M; Salson M; Macintyre E
    Methods Mol Biol; 2022; 2453():43-59. PubMed ID: 35622319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
    Brüggemann M; Kotrová M; Knecht H; Bartram J; Boudjogrha M; Bystry V; Fazio G; Froňková E; Giraud M; Grioni A; Hancock J; Herrmann D; Jiménez C; Krejci A; Moppett J; Reigl T; Salson M; Scheijen B; Schwarz M; Songia S; Svaton M; van Dongen JJM; Villarese P; Wakeman S; Wright G; Cazzaniga G; Davi F; García-Sanz R; Gonzalez D; Groenen PJTA; Hummel M; Macintyre EA; Stamatopoulos K; Pott C; Trka J; Darzentas N; Langerak AW;
    Leukemia; 2019 Sep; 33(9):2241-2253. PubMed ID: 31243313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
    Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-loci diagnosis of acute lymphoblastic leukaemia with high-throughput sequencing and bioinformatics analysis.
    Ferret Y; Caillault A; Sebda S; Duez M; Grardel N; Duployez N; Villenet C; Figeac M; Preudhomme C; Salson M; Giraud M
    Br J Haematol; 2016 May; 173(3):413-20. PubMed ID: 26898266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
    Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
    Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL.
    Chen H; Gu M; Liang J; Song H; Zhang J; Xu W; Zhao F; Shen D; Shen H; Liao C; Tang Y; Xu X
    Nat Commun; 2023 Nov; 14(1):7468. PubMed ID: 37978187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gene rearrangement pattern of immunoglobulin and T-cell receptor (Ig/TR) and its clinical characteristics in children with SET-NUP214 fusion gene-positive leukemia/lymphoma].
    Li WJ; Cui L; Gao C; Zhao XX; Liu SG; Xin YP; Zhang RD; Zhang DW; Wang B; Li ZG; Wu MY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1362-7. PubMed ID: 22169284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
    Logan AC; Vashi N; Faham M; Carlton V; Kong K; Buño I; Zheng J; Moorhead M; Klinger M; Zhang B; Waqar A; Zehnder JL; Miklos DB
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1307-13. PubMed ID: 24769317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection.
    Theunissen PMJ; de Bie M; van Zessen D; de Haas V; Stubbs AP; van der Velden VHJ
    Leuk Res; 2019 Jan; 76():98-104. PubMed ID: 30389174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
    Kotrova M; Trka J; Kneba M; Brüggemann M
    Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality Control for IG /TR Marker Identification and MRD Analysis.
    Fronkova E; Svaton M; Trka J
    Methods Mol Biol; 2022; 2453():91-99. PubMed ID: 35622322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol.
    Svaton M; Skotnicova A; Reznickova L; Rennerova A; Valova T; Kotrova M; van der Velden VHJ; Brüggemann M; Darzentas N; Langerak AW; Zuna J; Stary J; Trka J; Fronkova E
    Blood; 2023 Feb; 141(5):529-533. PubMed ID: 36240445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin/T-Cell Receptor Gene Rearrangement Analysis Using RNA-Seq.
    van der Velden VHJ; Bastian L; Brüggemann M; Hartmann AM; Darzentas N
    Methods Mol Biol; 2022; 2453():61-77. PubMed ID: 35622320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.
    Salson M; Giraud M; Caillault A; Grardel N; Duployez N; Ferret Y; Duez M; Herbert R; Rocher T; Sebda S; Quief S; Villenet C; Figeac M; Preudhomme C
    Leuk Res; 2017 Feb; 53():1-7. PubMed ID: 27930944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput sequencing of immunoglobulin heavy chain for minimal residual disease detection in B-lymphoblastic leukemia.
    Correia RP; Puga RD; Muto NH; Lee MLM; Torres DC; Hassan R; Bacal NS; Hamerschlak N; Campregher PV
    Int J Lab Hematol; 2021 Aug; 43(4):724-731. PubMed ID: 33393719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in childhood acute lymphoblastic leukemia using a low-cost PCR strategy.
    Assumpção JG; Ganazza MA; de Araújo M; Silva AS; Scrideli CA; Brandalise SR; Yunes JA
    Pediatr Blood Cancer; 2010 Dec; 55(7):1278-86. PubMed ID: 20730889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.
    Fries C; Burack WR
    Leuk Res; 2018 Dec; 75():15-22. PubMed ID: 30445235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease.
    Szczepański T; Langerak AW; Wolvers-Tettero IL; Ossenkoppele GJ; Verhoef G; Stul M; Petersen EJ; de Bruijn MA; van't Veer MB; van Dongen JJ
    Leukemia; 1998 Jul; 12(7):1081-8. PubMed ID: 9665194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How I investigate minimal residual disease in acute lymphoblastic leukemia.
    Correia RP; Bento LC; de Sousa FA; Barroso RS; Campregher PV; Bacal NS
    Int J Lab Hematol; 2021 Jun; 43(3):354-363. PubMed ID: 33423385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.